Increased expression of miR-222 is associated with poor prognosis in bladder cancer

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Zhang, Dong qing ^a   Zhou, Chang kuo ^a   Jiang, Xue wen ^a   Chen, Jun ^a   Shi, Ben kang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bladder cancer; microRNA 222; Prognosis

Indexed keywords

MICRORNA 222; MICRORNA; MIRN222 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PROTEIN EXPRESSION; RNA ANALYSIS; BLADDER; BLADDER TUMOR; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84905823814     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-241     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009, 374:239-249. 10.1016/S0140-6736(09)60491-8, 19520422.
3. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866. 10.1038/nrc1997, 17060945.
4. Meister G. miRNAs get an early start on translational silencing. Cell 2007, 131:25-28. 10.1016/j.cell.2007.09.021, 17923084.
5. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005, 309:1519-1524. 10.1126/science.1111444, 16141061.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
7. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355. 10.1038/nature02871, 15372042.
8. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev 2005, 15:410-415. 10.1016/j.gde.2005.06.012, 15979303.
9. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafre SA, Farace MG, Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007, 26:3699-3708. 10.1038/sj.emboj.7601790, 1949005, 17627278.
10. Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D. miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One 2013, 8:e66502. 10.1371/journal.pone.0066502, 3679042, 23776679.
11. Xu K, Liang X, Shen K, Sun L, Cui D, Zhao Y, Tian J, Ni L, Liu J. MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 2012, 318:2168-2177. 10.1016/j.yexcr.2012.04.014, 22677042.
12. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del Basso De Caro M, Martinez-Montero JC, Incoronato M, Nuovo G, Croce CM, Condorelli G. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 2012, 31:858-868. 10.1038/onc.2011.280, 21743492.
13. Sun C, Li N, Zhou B, Yang Z, Ding D, Weng D, Meng L, Wang S, Zhou J, Ma D, Chen G. miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27. Oncol Lett 2013, 6:507-512. 3789083, 24137356.
14. He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, Jiang F-N, Liu X, Zhong W-D. Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genomics 2013, 14:757. 10.1186/1471-2164-14-757, 4008360, 24191917.
15. Lee C, He H, Jiang Y, Di Y, Yang F, Li J, Jin C, Fu D. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Med Oncol 2013, 30:700.
16. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Ma˚nsson W, Rovira C, Ho¨glund M. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009, 124:2236-2242. 10.1002/ijc.24183, 19127597.
17. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sanchez-Carbayo M. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 2012, 180:1808-1815. 10.1016/j.ajpath.2012.01.034, 22426337.
18. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31:13-20. 10.1002/ijc.2910310104, 6339421.
19. Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Herault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer 2013,